<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167594</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A09</org_study_id>
    <nct_id>NCT02167594</nct_id>
  </id_info>
  <brief_title>Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers</brief_title>
  <official_title>18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive&#xD;
      supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2014</start_date>
  <completion_date type="Actual">July 11, 2016</completion_date>
  <primary_completion_date type="Actual">July 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flortaucipir Imaging in PSP, CBD and Healthy Volunteers</measure>
    <time_frame>baseline and 9 month scans</time_frame>
    <description>A PSP/CBD (PSP = progressive supranuclear palsy; CBD = corticobasal degeneration) targeted composite Standardized Uptake Value ratio (SUVr) was calculated as the voxel-weighted average from the regional SUVr values of the left, right, and total globus pallidus and the dentate nuclei of the cerebellum for both the baseline and 9 month PET scans. Additionally, a global cortical Alzheimer's Disease (AD)-targeted cortical SUVr was calculated. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Corticobasal Degeneration</condition>
  <arm_group>
    <arm_group_label>PSP Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers receiving a flortaucipir PET scan at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flortaucipir F18</intervention_name>
    <description>IV injection, 370 megabecquerel (MBq) (10 mCi)</description>
    <arm_group_label>CBD subjects</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>PSP Subjects</arm_group_label>
    <other_name>[F18]T807</other_name>
    <other_name>18F-AV-1451</other_name>
    <other_name>LY3191748</other_name>
    <other_name>Tauvid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain PET scan</intervention_name>
    <description>positron emission tomography (PET) scan of the brain 75-105 minutes post-injection</description>
    <arm_group_label>CBD subjects</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>PSP Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cognitively Healthy Volunteers&#xD;
&#xD;
          -  Mini-mental state examination (MMSE) ≥ 28&#xD;
&#xD;
          -  No history of cognitive decline or parkinsonian motor disorder&#xD;
&#xD;
        CBD and PSP subjects&#xD;
&#xD;
          -  Able to walk 10 steps with minimal assistance&#xD;
&#xD;
          -  MMSE ≥ 14 and ≤ 30&#xD;
&#xD;
          -  Subject has a reliable study partner who agrees to accompany subject to visits and&#xD;
             spends at least 5 hours per week with the subject&#xD;
&#xD;
        PSP subjects only&#xD;
&#xD;
          -  Meet National Institute of Neurological Disorders and Stroke - Society for Progressive&#xD;
             Supranuclear Palsy (NINDS-SPSP) probable or possible PSP criteria as modified for the&#xD;
             Neuroprotection and Natural History Parkinson Plus Syndromes (NNIPPS) clinical trial&#xD;
&#xD;
        CBD subjects only&#xD;
&#xD;
          -  Meets 2013 consensus criteria for possible or probable corticobasal degeneration,&#xD;
             corticobasal syndrome (CBS) subtype&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
          -  Have evidence of structural abnormalities such as vascular disease, large strokes or&#xD;
             severe white matter disease or other mass lesion on screening MRI&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Current clinically significant cardiovascular disease or clinically significant&#xD;
             abnormalities on screening electrocardiogram (e.g. corrected QT interval &gt;450 msec)&#xD;
&#xD;
          -  Have a history of risk factors for Torsades de Pointes (e.g. heart failure,&#xD;
             hypokalemia, family history of long QT syndrome)&#xD;
&#xD;
          -  Have a current clinically significant infectious disease, endocrine or metabolic&#xD;
             disease, pulmonary, renal or hepatic impairment, or cancer&#xD;
&#xD;
          -  Females of childbearing potential who are not surgically sterile, not refraining from&#xD;
             sexual activity or not using reliable methods of contraception&#xD;
&#xD;
          -  Have received or participated in a trial with investigational medications in the past&#xD;
             30 days&#xD;
&#xD;
          -  Have had a non-study related radiopharmaceutical imaging or treatment procedure within&#xD;
             7 days prior to the study imaging session&#xD;
&#xD;
          -  Have a history of neuroleptic use for a prolonged period of time or within the past 6&#xD;
             months&#xD;
&#xD;
        PSP and CBD subjects&#xD;
&#xD;
          -  Have evidence of amyloid deposition&#xD;
&#xD;
          -  Meet National Institute on Aging-Alzheimer's Association criteria for probable&#xD;
             Alzheimer's Disease&#xD;
&#xD;
          -  Have any other neurological condition other than CBS or PSP that could account for&#xD;
             cognitive or motor deficits&#xD;
&#xD;
          -  Serum or plasma progranulin level less than one standard deviation below the normal&#xD;
             subject mean for the laboratory performing the assay&#xD;
&#xD;
          -  Have a high-risk family history suggestive of tar DNA binding protein (TDP)-43&#xD;
             pathology or known mutations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Movement Disorder Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Neurosciences Clinical Research Unit</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molecular Neuroimaging</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2014</study_first_posted>
  <results_first_submitted>July 16, 2020</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2020</results_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited between Aug 2014 and Jul 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PSP Subjects</title>
          <description>Amyloid negative subjects with Progressive Supranuclear Palsy (PSP) receiving a flortaucipir PET scan</description>
        </group>
        <group group_id="P2">
          <title>CBD Subjects</title>
          <description>Amyloid negative subjects with Corticobasal Degeneration (CBD) receiving a flortaucipir PET scan</description>
        </group>
        <group group_id="P3">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers receiving a flortaucipir PET scan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PSP Subjects</title>
          <description>Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.&#xD;
Flortaucipir F18 PET scan: IV injection, 370 MBq (10 mCi)</description>
        </group>
        <group group_id="B2">
          <title>CBD Subjects</title>
          <description>Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.&#xD;
Flortaucipir F18 PET scan: IV injection, 370 MBq (10 mCi)</description>
        </group>
        <group group_id="B3">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers receiving a flortaucipir PET scan at baseline.&#xD;
Flortaucipir F18 PET scan: IV injection, 370 MBq (10 mCi)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.2" spread="5.88"/>
                    <measurement group_id="B2" value="72.2" spread="7.41"/>
                    <measurement group_id="B3" value="68.7" spread="10.41"/>
                    <measurement group_id="B4" value="69.8" spread="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental Status Exam (MMSE)</title>
          <description>Mini-mental status exam (MMSE) is a 30-point questionnaire that is used to measure cognitive impairment. Scores range from 0 to 30 with lower scores representing greater levels of cognitive impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" spread="3.12"/>
                    <measurement group_id="B2" value="26.3" spread="4.32"/>
                    <measurement group_id="B3" value="29.3" spread="0.58"/>
                    <measurement group_id="B4" value="26.7" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flortaucipir Imaging in PSP, CBD and Healthy Volunteers</title>
        <description>A PSP/CBD (PSP = progressive supranuclear palsy; CBD = corticobasal degeneration) targeted composite Standardized Uptake Value ratio (SUVr) was calculated as the voxel-weighted average from the regional SUVr values of the left, right, and total globus pallidus and the dentate nuclei of the cerebellum for both the baseline and 9 month PET scans. Additionally, a global cortical Alzheimer's Disease (AD)-targeted cortical SUVr was calculated. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.</description>
        <time_frame>baseline and 9 month scans</time_frame>
        <population>Healthy volunteers did not receive 9 month follow-up scans. 9 month data presented only for those subjects who completed both a baseline and 9 month scan.</population>
        <group_list>
          <group group_id="O1">
            <title>PSP Subjects</title>
            <description>Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.&#xD;
Flortaucipir F18 PET scan: IV injection, 370 MBq (10 mCi)</description>
          </group>
          <group group_id="O2">
            <title>CBD Subjects</title>
            <description>Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.&#xD;
Flortaucipir F18 PET scan: IV injection, 370 MBq (10 mCi)</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteers</title>
            <description>Healthy volunteers receiving a flortaucipir PET scan at baseline.&#xD;
Flortaucipir F18 PET scan: IV injection, 370 MBq (10 mCi)</description>
          </group>
          <group group_id="O4">
            <title>All Subjects</title>
            <description>All subjects combined</description>
          </group>
        </group_list>
        <measure>
          <title>Flortaucipir Imaging in PSP, CBD and Healthy Volunteers</title>
          <description>A PSP/CBD (PSP = progressive supranuclear palsy; CBD = corticobasal degeneration) targeted composite Standardized Uptake Value ratio (SUVr) was calculated as the voxel-weighted average from the regional SUVr values of the left, right, and total globus pallidus and the dentate nuclei of the cerebellum for both the baseline and 9 month PET scans. Additionally, a global cortical Alzheimer's Disease (AD)-targeted cortical SUVr was calculated. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.</description>
          <population>Healthy volunteers did not receive 9 month follow-up scans. 9 month data presented only for those subjects who completed both a baseline and 9 month scan.</population>
          <units>standardized uptake value ratio (SUVr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Dentate Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.12"/>
                    <measurement group_id="O2" value="1.12" spread="0.04"/>
                    <measurement group_id="O3" value="1.03" spread="0.12"/>
                    <measurement group_id="O4" value="1.15" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Dentate 9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.11"/>
                    <measurement group_id="O2" value="1.11" spread="0.05"/>
                    <measurement group_id="O4" value="1.15" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Dentate Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.10"/>
                    <measurement group_id="O2" value="1.09" spread="0.04"/>
                    <measurement group_id="O3" value="1.08" spread="0.07"/>
                    <measurement group_id="O4" value="1.14" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Dentate 9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.11"/>
                    <measurement group_id="O2" value="1.08" spread="0.05"/>
                    <measurement group_id="O4" value="1.12" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Globus Pallidus Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.15"/>
                    <measurement group_id="O2" value="1.40" spread="0.20"/>
                    <measurement group_id="O3" value="1.29" spread="0.06"/>
                    <measurement group_id="O4" value="1.53" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Globus Pallidus 9 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.13"/>
                    <measurement group_id="O2" value="1.47" spread="0.19"/>
                    <measurement group_id="O4" value="1.55" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Globus Pallidus Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.15"/>
                    <measurement group_id="O2" value="1.56" spread="0.32"/>
                    <measurement group_id="O3" value="1.30" spread="0.07"/>
                    <measurement group_id="O4" value="1.58" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Globus Pallidus 9 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.15"/>
                    <measurement group_id="O2" value="1.62" spread="0.40"/>
                    <measurement group_id="O4" value="1.62" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global PSP/CBD Summary Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.10"/>
                    <measurement group_id="O2" value="1.29" spread="0.11"/>
                    <measurement group_id="O3" value="1.17" spread="0.03"/>
                    <measurement group_id="O4" value="1.34" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global PSP/CBD Summary 9 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.09"/>
                    <measurement group_id="O2" value="1.32" spread="0.13"/>
                    <measurement group_id="O4" value="1.36" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD Cortical Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.03"/>
                    <measurement group_id="O2" value="0.99" spread="0.06"/>
                    <measurement group_id="O3" value="1.02" spread="0.02"/>
                    <measurement group_id="O4" value="0.99" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AD Cortical 9 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.03"/>
                    <measurement group_id="O2" value="1.00" spread="0.05"/>
                    <measurement group_id="O4" value="0.99" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>End of study for AE reporting was 48 hours after flortaucipir administration at each imaging visit.</time_frame>
      <desc>Adverse Events were defined as occurring or worsening after injection of dose, within 48 hours post injection, at an imaging visit. AEs occurring after study drug administration, but outside that window were not recorded, unless considered attributable to flortaucipir.</desc>
      <group_list>
        <group group_id="E1">
          <title>PSP Subjects</title>
          <description>Amyloid negative subjects with Progressive Supranuclear Palsy (PSP) receiving a flortaucipir PET scan</description>
        </group>
        <group group_id="E2">
          <title>CBD Subjects</title>
          <description>Amyloid negative subjects with Corticobasal Degeneration (CBD) receiving a flortaucipir PET scan</description>
        </group>
        <group group_id="E3">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers receiving a flortaucipir PET scan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.0</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bronchial secretion retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Avid Radiopharmaceuticals, Inc.</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

